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Abstract
Background: Several c-MET targeting inhibitory molecules have already shown promising results in the treatment
of patients with Non-small Cell Lung Cancer (NSCLC). Combination of EGFR- and c-MET-specific molecules may
overcome EGFR tyrosine kinase inhibitor (TKI) resistance. The aim of this study was to allow for the identification of
patients who might benefit from TKI treatments targeting MET and to narrow in on the diagnostic assessment of MET.
Methods: 222 tumor tissues of patients with NSCLC were analyzed concerning c-MET expression and activation in
terms of phosphorylation (Y1234/1235 and Y1349) using a microarray format employing immunohistochemistry (IHC).
Furthermore, protein expression and MET activation was correlated with the amplification status by Fluorescence in
Situ Hybridization (FISH).
Results: Correlation was observed between phosphorylation of c-MET at Y1234/1235 and Y1349 (spearman correlation
coefficient rs = 0.41; p < 0.0001). No significant correlation was shown between MET expression and phosphorylation
(p > 0.05). c-MET gene amplification was detected in eight of 214 patients (3.7 %). No significant association was
observed between c-MET amplification, c-MET protein expression and phosphorylation.
Conclusion: Our data indicate, that neither expression of c-MET nor the gene amplification status might be the best
way to select patients for MET targeting therapies, since no correlation with the activation status of MET was observed.
We propose to take into account analyzing the phosphorylation status of MET by IHC to select patients for MET
targeting therapies. Signaling of the receptor and the activation of downstream molecules might be more crucial for
the benefit of therapeutics targeting MET receptor tyrosine kinases than expression levels alone.
Keywords: Non-small cell lung Cancer (NSCLC), MET, Targeted therapies, Diagnostic, Phosphorylated MET,
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Background
Targeted therapies constitute promising strategies in the
personalized treatment of cancer. Increasing knowledge of
expression patterns and molecular pathophysiology led to
improved outcomes of patients with non-small cell lung
cancer (NSCLC). The Mesenchymal Epithelial Transition
factor (MET) receptor tyrosine kinase (RTK) and its ligand
hepatocyte growth factor/scatter factor (HGF/SF) are pre-
dominantly involved in epithelial-to-mesenchymal transi-
tion (EMT) [1] and tissue regeneration [2]. Binding of
HGF induces MET dimerization that induces tyrosine kin-
ase activation by phosphorylation of the tyrosine residues
Y1230, Y1234 and Y1235, which then activates various
downstream signaling cascades [3]. Activated MET recep-
tor signaling promotes tumor angiogenesis, tumor cell
invasion and metastasis [4, 5]. This constitutive activation
is thought to be due to MET overexpression, gene amplifi-
cation and mutations within the tyrosine kinase domain
* Correspondence: i.watermann@lungenclinic.de
1Clinical and Experimental Pathology, Research Center Borstel, Borstel,
Germany
2LungenClinic Grosshansdorf, Grosshansdorf, Germany
Full list of author information is available at the end of the article
© 2015 Watermann et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Watermann et al. Diagnostic Pathology  (2015) 10:130 
DOI 10.1186/s13000-015-0362-5
and correlates with poor clinical outcome in patients with
lung cancer [3, 6–10].
Several MET-targeting inhibitors have already shown
promising data in clinical trials [11–13]. Most of them
are tyrosine kinase inhibitors followed by antagonistic
antibodies [14, 15]. Onartuzumab, a recombinant, fully
humanized monovalent, monoclonal antibody binds to
the extracellular domain of MET, thus blocking binding
of HGF and thereby the activation [16, 17]. Spigel et al.
conducted a randomized phase II trial of onartuzumab
in combination with erlotinib in patients with advanced
NSCLC [18]. Onartuzumab plus erlotinib was associated
with improved progression-free survival (PFS) and over-
all survival (OS) in the MET-positive population. Never-
theless, the phase III clinical study for this antibody was
stopped because the results of phase II could not be
confirmed. The onartuzumab/erlotinib combo did not
show an overall survival benefit for the patients, even in
the high expressers of MET [19].
Tivantinib, a c-MET selective, small molecule inhibits
MET phosphorylation leading to reduced capacity of in-
vasion, proliferation and metastasis [20, 21]. Results from
the MARQUEE trial corroborate an OS benefit for pa-
tients with locally advanced or metastatic non-squamous
MET-high lung cancer who received chemotherapy prior
to treatment with tivantinib in combination with erloti-
nib. Unfortunately, the primary end point or improved
OS for the whole group was not met.
Crizotinib, a non-selective MET inhibitor targeting
c-MET, ALK and ROS1 exhibits its antitumoral effect
in c-MET, ALK-positive and ROS positive patients
[11, 22, 23] demonstrating the need of MET determin-
ation. The expression of MET was not evaluated in these
studies. In addition, concurrent inhibition of VEGFR2 and
MET is discussed for anti-angiogenesis therapy, also for
NSCLC [24].
MET amplification leads to gefitinib resistance in lung
cancer patients lacking the point mutation T790M in
exon 20 of EGFR [6]. Bean et al. have also shown that
MET amplification occurs in human lung adenocarcin-
omas independently of T790M with resistance to gefi-
tinib or erlotinib, emphasizing the relevant therapeutic
target of MET for patients with acquired resistance to
EGFR kinase inhibitors. Combination of EGFR and MET
inhibitory molecules may overcome EGFR TKI resist-
ance in patients with NSCLC [6]. MET as target of sev-
eral multi TKIs, together with the prognostic value of
MET expression demonstrating the relevance to evaluate
MET on several levels. The challenge is to identify pa-
tient subgroups who respond to MET inhibitors. For
that reason the main goal is to establish a reliable pre-
dictive assay for the determination of the MET status.
For that purpose, we investigated in a retrospective
study, MET expression on protein level by IHC using
antibody clone SP44 in 222 formalin fixed paraffin
embedded (FFPE) - and HOPE (HEPES-Glutamic Acid
Buffer Mediated Organic Solvent Protection Effect) fixed -
NSCLC tissues. Because not only expression but also
activation of MET is essential for tumor progression,
we also analyzed the phosphorylation status of the
receptor by IHC with two phosphorylation specific
antibodies. To obtain more insights into the relation be-
tween MET expression, phosphorylation and amplifica-
tion, MET amplification was assessed by FISH analysis.
For a limited number of tumor samples, MET expression
was also evaluated on mRNA level and compared with
MET expression evaluated by Western Blot analysis.
Finally, we compared MET- and EGFR-expression within
these tumor tissues to investigate, whether a correlation
exists between both biomarkers. The aim of the present
study was to assess, if the expression and amplification is
correlated with the activation status of the MET receptor,
because we hypothesize, that not only expression and
amplification but phosphorylation can be a relevant marker
to select patients for MET specific therapies.
Methods
Patients and tissues
A total of 222 lung tumor specimens from patients with
NSCLC were obtained from the Biomaterial Bank North
after resection from the surgical department of Lungen-
Clinic Grosshansdorf (Table 1), including 110 cases of
adenocarcinoma (ADC), 86 cases of squamous cell car-
cinoma (SCC), 12 cases of large cell carcinoma (LCC), 6
cases of carcinoids and 2 cases of adeno-squamous car-
cinoma. This retrospective study was performed in com-
pliance with the ethical committee of the University of
Lübeck (reference number 12–220). All tumor samples
were histologically classified according to the Inter-
national Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society
International Multidisciplinary classification of lung
adenocarcinoma 2011 [25] and WHO guidelines 2010
[26]. The lung cancer tissue samples were fixed both with
formalin and in parallel using the alternative HOPE tech-
nique and were subsequently embedded in paraffin [27].
Established clinical and histological factors of all tested
patients were included in this study (patient age, gender,
histology, TNM classification, smoking status; Table 1).
Tissue microarray (TMAs) construction
Specimens were arranged on TMAs for enhanced
comparability of immunohistochemical stainings as pre-
viously described [28]. Appropriate formalin and HOPE-
fixed -paraffin embedded A549 cell line known to express
c-MET basal, was used as control. Representative tumor
punches (2 mm in diameter) of two core biopsies were
taken from two viable parts of each tumor block using the
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Beecher manual arrayer (Beecher instruments, Alpha,
Metrix Biotech). This approach should enhance repre-
sentative analyzing of immunohistochemical stainings
and FISH analyzes.
Immunohistochemistry (IHC)
MET protein expression was assessed by IHC on 2 μm
thick deparaffinized TMA sections, using rabbit anti-
human c-Met monoclonal antibody (clone SP44) (Spring
Biosciences, Pleasanton, CA, USA) directed against
the synthetic peptide derived from C-terminus of human
c-Met protein displaying membranous and/or cytoplasmic
epitope. Staining procedures were conducted according to
manufacturer’s protocol in a final 1:1000 dilution.
Phosphorylated MET-expression was assessed by two
different primary antibodies purchased from Cell Signaling
(Danvers, MA). Phospho-Met (Y1234/1235) (D26) and
Phospho-Met (Y1349) (130H2) in a final dilution of 1:100.
HOPE-fixed, paraffin-embedded sections were depar-
affinized by xylene incubation (two times 10 min) before
SP44 was applied for 30 min at room temperature.
Endogenous peroxidases were blocked by incubation
with 3 % H2O2 for 10 min. Negative controls omitting
the primary antibody were always included.
Formalin-fixed samples from the same tumors were
deparaffinized following standard procedure. Antigen re-
trieval was achieved by boiling in citrate buffer (10 mM,
pH 6.0) for 10 min (Merck KGaA, Darmstadt, Germany)
with subsequent cooling at room temperature for 20 min.
Antigen detection was carried out with DAB substrate kit
(DAB chromogen and DAB substrate), used for 15 min to
visualize specific binding. Sections were counterstained
using Meyer’s hemalum and mounted with Pertex (Medite
GmbH, Burgdorf, Germany) for further evaluation.
Evaluation of Met IHC staining
Two observers quantified staining intensities. Samples were
evaluated with the MET scoring algorithm as previously
described [18]. MET positivity was defined when scored as
2+ and 3+. 3+ was selected if ≥ 50 % of tumor cells stained
with strong intensity; 2+ was defined if ≥ 50 % of tumor
cells showed moderate or higher staining but < 50 % with
strong intensity; 1+ if ≥ 50 % of tumor cells with weak or
higher staining but < 50 % with moderate or higher inten-
sity; 0 was defined if no staining or <50 % of tumor cells
with any intensity.
Phosphorylated MET expression was evaluated ac-
cording to the intensity of cytoplasmic staining (no
staining = 0, weak staining = 1, moderate staining = 2,
strong staining = 3) and the percentage of stained tumor
cells (0 % = 0, 1-10 % = 1, 11-50 % = 2, >50 % = 3). If ≥
50 % of tumor cells showed staining intensity ≥ 2, tumor
samples were categorized as positive in this study.
EGFR scoring methodology
EGFR expression is considered as positive, if ≥10 % of
the tumor cells show membranous staining of any inten-
sity using x10 and x20 magnification assessed by Dako
EGFR PharmDx data sheet.
Fluorescence in situ hybridization
c-MET gene copy numbers were assessed by fluorescence
in situ hybridization (FISH) using ZytoLight SPEC MET/
CEN7 Dual Color Probe (Zytovision, Bremerhafen,
Germany). Before hybridization, sections were deparaffi-
nized, dehydrated and immersed in citrate buffer (Merck
KGaA, Darmstadt, Germany) pH 6 at 98 °C for 15 min,
and subsequently washed twice in distilled water for
2 min. The sections were air dried and pretreated with
pepsin for 5 min before denatured for 10 min at 75 °C.
Table 1 Characteristics of 222 patients with Non-small cell lung
cancer
Category Subcategory Results (%)
Age ≥65 154 (69.4 %)
<65 68 (30.6 %)
Gender Male 142 (63.9 %)
Female 80 (36.1 %)
aSmoking status Current 67 (30.1 %)
Former 101 (45.5 %)
Never 23 (10.4 %)
unknown 31 (14 %)
aAsbestos contact Present 17 (7.7 %)
Absent 49 (22.1 %)
aCOPD Present 43 (15.3 %)
Absent 5 (2.3 %)
Histologic type ADC 110 (49.5 %)
SCC 94 (42.3 %)
LCC 9 (4.1 %)
Other 9 (4.1 %)
Tumor size T1 43 (19.4 %)
T2 125 (56.3 %)
T3 32 (14,4 %)
T4 22 (9.9 %)
Lymph node status N0 106 (47.7 %)
N1 52 (23.4 %)
N2 47 (21.2 %)
N3 17 (7.7 %)
Stage I 72 (32.4 %)
II 61 (27.5 %)
III 79 (35.6 %)
IV 10 (4.5 %)
aHistory of smoking, contact with asbestos and chronic obstructive pulmonary
disease (COPD) were undetermined in the rest of the patients
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After hybridization at 37 °C for 20 h, slides were washed
and counterstained with 1.5 μg/ml 4’,6’-diamidino-2-
phenylindole (DAPI) mounting medium (Vectashield, Vec-
tor laboratories, Burlingame, CA) and coverslips were fixed
with nail polish.
Analysis of FISH signals was performed on an epifluores-
cence microscope Nikon Eclipse 80i H550L (Nikon) with
interference filters (AHF Analysentechnik AG, Tübingen,
Germany).
At least 50 non-overlapping interphase nuclei of tumor
cells were counted per core. The nuclei were selected
using the DAPI filter under high magnification (x600).
For each probe, the numbers of c-MET and CEN7 per
nuclei were separately scored and mean cMET/CEN7 ra-
tio was determined. FISH MET gene amplification was
defined as FISH positive, when
a) MET/CEP7 ratio was > 2.2 or
b) small gene clusters (≥4 copies) independent of the
MET to CEP 7 ratio
These analysis criteria were adapted to previous publi-
cations for the evaluation of MET amplification [7].
Increased MET gene copy number (GCN) >3 of
Chromosome 7 and MET-locus was defined as polysomy.
Evaluation was performed independently by two scien-
tists well-vised in FISH analysis.
Protein extraction, SDS-PAGE, and western blotting
HOPE-fixed, paraffin-embedded specimens were deparaffi-
nized as previously described by Olert et al. [27]. Protein
extraction was performed using lysis buffer (7 M urea, 2 M
thiourea, 100 mM dithiothreitol (DTT), 4 % CHAPS (3-[3-
Cholamidopropyl)-dimethyl-ammonio]-1-propansulfonat),
2 % IGEPAL, 1 % Triton X, 5 mM PMSF, 0.5 mM EDTA,
40 mM Tris). Protein concentration was determined by
Bradford with Coomassie (Bradford) Protein Assay Kit
(Pierce, Rockford, IL, USA). Forty μg of whole protein lys-
ate was separated by gel electrophoresis and analyzed by
Western Blot using nitrocellulose membrane using iblot
gel transfer system (Invitrogen, Germany). After blocking
with 5 % nonfat dry milk (1 h, ambient temperature),
membranes were incubated with Met-specific antibody
clone SP44 (1:1000) in TBS-0.05 % Tween overnight (4 °C).
The following day, the membrane was washed three times
in TBS-0.05 % Tween before adding secondary antibody anti
rabbit HRP (Cell Signaling) for 1 h at room temperature.
Development was achieved using ECL solution and expos-
ure to film. Intensities of appropriate MET specific bands
were analyzed by band leader.
Quantitative real-time PCR of MET mRNA
Total RNA was isolated from HOPE-fixed tissue samples
as described previously [29] using RNeasy minikit (Qiagen)
according to the manufactures protocol. RNA integrity
and concentration were determined with the Agilent
RNA 6000 Nano Assay Bioanalyzer (Agilent, Böblingen,
Germany). 1 μg of RNA was transcribed into cDNA
with the Maxima first strand cDNA synthesis kit for RT-
qPCR (Thermos Scientific). Genomic DNA was digested
with DNase I within cDNA synthesis. RPL32 was used to
normalize differences in input cDNA amounts. Intron
spanning primers were designed with the Universal Probe
Library (Roche Applied Sciences, Germany). Primers were
used as follows: Forward primer 5’-TGAAATTCATCC
AACCAAATCTT-3’ and reverse primer 5’- AATAGAA
AACTGACAATGTTGAGAGG-3’ (probe no. 31) for MET
and forward primer 5’- CCACCGTCCCTTCTCTCTT-3’
and reverse primer 5’- GGGCTTCACAAGGGGTCT-3’
(probe no. 10) for RPL32. Amplification was performed
with Light Cycler 480II from Roche Diagnostics. After
initial denaturation at 95 °C for 5 min, amplification
protocol consisted of 45 cycles (10 s at 95 °C and 30 s
at 60 °C) using Light Cycler 2x Probe Master Mix,
0.4 μM oligonucleotides and 0.2uM 6-carboxyfluorescein
(FAM)-labeled hydrolysis probes (Roche Applied Science)
in a final volume of 10 μl. Standard curve was made from
serial dilution of template cDNA. Expression levels were
calculated after normalization with RPL32.
Statistical analysis
All statistical analysis in this study were performed with
Spearman’s rank nonparametric correlation test using
Prism 6 software. All reported p values are two sided
(GraphPad Prism version 6.0 Software, San Diego, CA).
Results
Patient characteristics
A total of 222 surgically resected NSCLC patients were
included in this study. Clinical parameters are summa-
rized in Table 1. 110 tumors (49.5 %) were classified as
adenocarcinoma (ADC), 94 (42.3 %) were grouped as
squamous cell carcinoma (SCC), 9 (4.1 %) as large cell
carcinoma (LCC) and 9 (4.1 %) as other tumors (typical
and atypical carcinoids). According to WHO classification
2010, pathological TNM staging distributed the patients
as followed: 29 (13 %) of patients were classified as IA,
43 (19.4 %) were classified as IB 40 (18 %) were IIA,
21 (9.5 %) IIB, 56 (25.2 %) were IIIA, 23 (10.4 %) were
classified as IIIB and 10 (4.5 %) were grouped to IV
(Table 1).
MET protein expression evaluated by IHC in FFPE- versus
HOPE fixed NSCLC tissues
We compared staining intensities of the MET specific
antibody clone SP44 in formalin fixed paraffin embedded
tissue versus HOPE-fixed tumor samples. When MET
expression was evaluated in HOPE-fixed samples, staining
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intensities were mostly stronger compared to the appro-
priate FFPE tissue samples within one specimen (Fig. 1).
In FFPE NSCLC tissues, 209 samples could be analyzed
concerning their staining intensities. 45 (21.5 %) were
scored as MET positive (2+). None of the FFPE tissues
showed cMET expression of 3+. Negative MET expres-
sion was observed for 164 (78.5 %) tumor samples 53
(25.4 %) cases were scored as 0, and 111 (53.1 %) tumor
samples were scored as 1). Of the ADC subtype, 34
(16.2 %) were scored as MET positive, of the SCC subtype
10 (4.8 %) and of the LCC 1 (0.5 %) (Table 2).
Of the corresponding 209 HOPE fixed NSCLC tissues,
77 (36.8 %) were scored positive (72 (34.4 %) of the tumor
samples were scored as 2+ and 5 (2.4 %) were classified as
3+). Negative MET expression was shown for 132 (63.2 %)
tumor tissue samples (28 (13.4 %) samples were scored as
0 and 104 (49.8 %) samples were scored as 1) (Fig. 2a).
Subtype classification of HOPE fixed tumor yielded in
54 (25.8 %) MET positivity for ADC, 23 (11 %) for
SCC, none of LCC and other subtypes showed MET
expression (Table 2).
There was no significant association with clinical char-
acteristics and also not with the histological entities
(data not shown). Of 77 (36.8 %) HOPE positive samples
and 45 (21.5 %) FFPE- positive samples, the intersection
between HOPE and formalin fixed tumor tissue was 29
(13.9 %) (Fig. 2b). Mean MET IHC score was 0.962 (SD
0.685) for FFPE tumor tissue samples and 1.258 (SD
0.714) for the appropriate HOPE fixed samples (Fig. 2c).
Correlation between c-Met expression evaluated by IHC
in FFPE versus HOPE fixed samples was shown (spearman
correlation coefficient rs = 0.482 p < 0.0001). Correlation
with any clinicopathological status was not shown.
Expression of activated MET [Y1234/1235] and [Y1349];
correlation between MET expression and phosphorylation
Of 222 patients, 213 tumor samples could be evaluated
for phosphorylation at Y1234/1235 (autophosphorylation
Fig. 1 Examples of NSCLC tissues stained for immunohistochemical quantification of MET differences between FFPE- and HOPE-fixed tumor samples,
stained with MET specific antibody clone SP44 (original magnification x 400). a + b) same specimen. a FFPE: MET expression scored 0; b HOPE fixed
sample; MET expression scored 1+. (c + d) one specimen. c FFPE: MET expression scored 1+; d HOPE fixed sample; MET expression scored 2+. (e + f)
one specimen. e FFPE: MET expression scored 2+; f HOPE fixed sample; MET expression scored 3+
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site). 30 (14 %) tumor tissue samples showed Met phos-
phorylation. Of 209 tumor tissues, evaluated by IHC for
the expression of MET and positive for phosphorylation
at Y1234/1235, 20 (9.6 %) were classified as ADC, 9
(4.3 %) were categorized as SCC and 1 (0.5 %) as LCC.
For phosphorylation at Y1349 (docking site of MET), 215
tissues could be analyzed. 38 (17.7 %) samples were phos-
phorylated at that phosphorylation site. Classified into the
corresponding histological entities, MET phosphorylation
of Y1349 was present in 17 (8.1 %) of ADC, 18 (8.6 %) of
SSC and 3 (1.4 %) of LCC related to the 209 tissues
evaluated for MET expression (Table 2).
Correlation between phosphorylation of MET at Y1234/
1235 and Y1349 was determined with rs = 0.41; p < 0.0001).
Staining patterns for phosphorylated MET (Y1234/1235
and Y1349) were both cytoplasmic and membranous. Im-
munoreactivity was exclusively restricted to tumor cells
(Fig. 3). Next, correlation between phosphorylated MET
and expression was evaluated. For that purpose, expression
and phosphorylation were categorized into positive and
negative as described above. Relationship between MET
expression and phosphorylation was unverifiable. Correl-
ation between MET expression and phosphorylation was
neither shown for Y1234/1235 nor for Y1349. (spearman
correlation coefficient rs = 0.054, p > 0.05 for Y1234/1235
and MET expression and rs = 0.017, p > 0.05 for Y1349 and
MET expression). Likewise, no association with any clini-
copathological parameter was shown.
MET gene copy numbers evaluated by FISH
Out of total of 444 tumor samples (222 patients in dupli-
cates), valid results were obtained for 214 patients (96.4 %).
Invalid results were due to the lack of adequate tumor cells.
C-MET gene amplification was detected in eight of 214 pa-
tients (3.7 %). Concerning the 209 tumor tissues evaluated
for MET expression, percentage acounts 3.8 %. These clus-
tered gene amplifications showed mean ratio range between
1.5 and 6.26 (cMET/CEN7 ratio), distributed in 5 (2.4 %) of
ADC and 3 (1.4 %) of SCC whereas no amplification was ob-
served in LCC and other tumor entities (Table 2). Polyso-
mies were evident in 2.3 % of analyzed tumor
samples (corresponds to 2.4 % of 209 tumor samples
analyzed for MET expression). Thereof, 3 (1.4 %) were ADC,
and 2 (1 %) were LCC, no polysomies were observed in SCC
and other tumor entities (Table 2). Different FISH patterns
are shown in Figure 4.
Correlation between MET amplification, MET protein
expression, and activation
No significant association was observed between c-MET
amplification and MET protein expression or phosphoryl-
ation (MET amplification and MET expression Formalin:
spearman correlation coefficient rs =0.06, p > 0.05; MET
amplification and MET expression HOPE rs <0, p > 0.05;
MET amplification and phosphorylation at Y1234/1235:
spearman correlation coefficient rs =0.089, p > 0.05; amplifi-
cation and phosphorylation at Y1349: spearman correlation
coefficient rs =0.052, p > 0.05).
MET gene copy number correlated with tumor size by
trend and lymph node status (both: spearman correlation
Table 2 Relationship between histological entities and MET protein
expression and gene copy number in 209 patients with NSCLC
Histology versus MET expression (formalin)
All MET positive MET negative
(formalin) (formalin)
Histology (%) 209 (94.1) 45 (21.5) 164 (78.5)
ADC 110 (48.2) 34 (16.2) 71 (34)
SCC 94 (42.3) 10 (4.8) 77 (36.8)
LCC 9 (4) 1 (0.5) 8 (3.8)
other 9 (4) 0 8 (3.8)
Histology versus MET expression (HOPE)
All MET positive MET negative
(HOPE) (HOPE)
Histology (%) 209 (94.1) 77 (36.8) 132 (63.2)
ADC 110 (48.2) 54 (25.8) 51 (24.4)
SCC 94 (42.3) 23 (11) 64 (30.6)
LCC 9 (4) 0 (0) 9 (4.3)
other 9 (4) 0 (0) 8 (3.8)
Histology versus MET phosphorylation at Y1234/1235
All Y1234/1235+ Y1234/1235-
Histology (%) 209 (94.1) 30 (14.4) 179 (85.6)
ADC 110 (48.2) 20 (9.6) 87 (41.6)
SCC 94 (42.3) 9 (4.3) 77 (36.9)
LCC 9 (4) 1 (0.5) 7 (3.3)
other 9 (4) 0 8 (3.8)
Histology versus MET phosphorylation at Y1349
All Y1349+ Y1349-
Histology (%) 209 (94.1) 38 (18.1) 171 (81.8)
ADC 110 (48.2) 17 (8.1) 91 (43.5)
SCC 94 (42.3) 18 (8.6) 67 (32.1)
LCC 9 (4) 3 (1.4) 5 (2.4)
other 9 (4) 0 8 (3.8)
Histology versus MET gene copy number
All FISH positive FISH positive
(amplification) (polysomy)
Histology (%) 209 (94.1) 8 (3.8) 5 (2.4)
ADC 110 (48.2) 5 (2.4) 3 (1.4)
SCC 94 (42.3) 3 (1.4) 0 (0)
LCC 9 (4) 0 (0) 2 (1)
other 9 (4) 0 (0) 0 (0)
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coefficient rs = 0.132; p = 0.012). No association was found
for any other clinical characteristic. (MET amplification is
composed of real amplification plus polysomies).
Quantification of MET by IHC, western blot analysis and
real-time PCR (mRNA-level)
Relationship between MET determination on mRNA-level,
protein level, DNA-level and the activated MET receptor
A few NSCLC tissue samples (11 tumor samples are
shown) could be selected for the comparison of MET ex-
pression levels evaluated on protein level by IHC and west-
ern blot analysis and on mRNA-level by real-time PCR.
Strong relationship is observed between IHC and western
blot analysis (Fig. 5). Whereas no explicit connection is
found between the expression on protein level and mRNA
level, independently of evaluating the protein level of MET
by IHC or western blot analysis (Fig. 5).
Correlation between EGFR expression and MET expression
evaluated by IHC
In a previous publication, we analyzed EGFR expression by
different EGFR specific antibody clones [30]. Therefore, we
were interested in the relationship between MET – and
EGFR- expression. Correlation between MET-and EGFR-
Fig. 2 a Distribution of positive and negative MET expression of NSCLC samples. b Intersection of MET positive Formalin- and HOPE- fixed NSCLC
samples. c Mean of MET intensities of Formalin- versus HOPE- fixed NSCLC samples
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Fig. 3 Examples for immunohistochemical Analysis of activated p-MET [Y1234/1235] and [Y1349] in NSCLC tumor tissues (original magnification x
400). a Phosphorylation of Y1234/1235. b Phosphorylation of Y1349
Fig. 4 MET gene copy numbers evaluated by FISH analysis
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expression, evaluated with antibody clone 31G7, was deter-
mined. (Spearman correlation coefficient rs = 0.2086; p =
0.0026). 207 tumor tissues could be analyzed for both MET-
and EGFR-expression. 185 tumor samples were scored as
positive for the expression of EGFR, 44 were scored positive
for MET expression and 43 tumor tissues were double posi-
tive for EGFR and MET. Thus, nearly all of MET expressing
tumor samples were also positive for MET expression.
Discussion
Personalized therapies will only be effective if target
molecules are exactly determined or quantified. MET is
currently one of the target proteins that are utilized for
several anticancer therapies in patients with NSCLC
[14, 15, 31]. State of the art methods for the determination
of MET have been previously conducted by IHC and FISH-
analysis. Within the present study, we show for the first
time combined analysis of MET expression on protein-,
mRNA-, and DNA-level together with the investigation of
activated MET RTK by immunohistochemistry. We demo-
nostrated that in resected specimens no correlation exists
between MET-expression and -phosphorylation. In fact,
activated MET is a potential target for small molecule
tyrosine kinase inhibitors that already have entered
clinical trials.
Dziadziuszko et al. [32] demonstrated a significant cor-
relation between MET gene copy number determined by
SISH and protein expression evaluated by IHC. In the
METLung clinical trial [18] of Spiegel et al., IHC was
assessed using antibody clone SP44 for the determin-
ation of MET-expression. Patients with 2+ or 3+ MET
expression of their tumours were included. They were
stratified for the level of MET expression. There was no
improvement in PFS or OS in the Intention-To-Treat
(ITT) population. Expression of c-MET was associated
with worse outcome. Apparently, the addition of onartu-
zumab to erlotinib in MET-positive patients abrogates
the negative prognostic impact. But, without a diagnostic
hypothesis, the results obtained in the (ITT) population
lead to interrupt the development of onartuzumab. One
reason for the weak responsiveness might be that not
only the expression level of c-met is relevant, but also
the status of receptor signaling.
In the trial of Spigel et al. [33] 52 % of patients were
scored as MET positive compared to 25 % in the study
of Dziadziuszko et al. [32] and 21.1 % of FFPE tumor tis-
sue versus 36.8 % HOPE fixed tumor samples in our
population. The high number of MET IHC positivity is
estimated to the fact, that in the METLung trial patients
with advanced NSCLC were analyzed. The difference be-
tween FFPE and HOPE fixed tumor samples might be
explained by the assumption that HOPE fixed tissues
generally reflect a more de facto protein expression as a
consequence of improved preservation of antigenicity
Fig. 5 Quantification of MET. Comparison of IHC, Western Blot
Analysis and Real-Time PCR
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[34]. Nevertheless, a correlation between c-Met expres-
sion of FFPE and HOPE-fixed samples was shown. The
intersection of FFPE- and HOPE fixed tissues accounted
13.9 %, demonstrating, that the majority of FFPE tissues
is included in the HOPE-fixed c-MET positive deter-
mined group of samples. We did not observe any correl-
ation with the clinicopathological status of the patients,
even not with the histologic types and stage, independ-
ently of the fixation method.
There are many studies evaluating the expression level
of c-MET, but only few that investigated phosphory-
lated c-MET in human cancer tissues. Whether MET-
expression is correlated with its phosphorylation status
in NSCLC tissue, still remains unclear. Recently, in the
case of gastric cancer, Inoue et al. [35] have shown, that
expression of c-MET and its phosphorylation are not al-
ways correlated. Whereas, Nakamura et al. [36], observed
overexpression of c-MET in 74.6 % of 130 surgically
resected ADC, phosphorylation of Y1235 was detected in
21.5 %. In addition, phosphorylated c-MET was correlated
with high levels c-MET expression (P = 0.0303) [36].
In our study, MET phosphorylation at Y1234/1235
was detected in 14 % of the investigated NSCLC tumor
samples, phosphorylation of Y1349 was observed in 17.7 %.
No association between MET expression and phosphoryl-
ation was found. In contrast to the study of Nakamura et
al., differences might be due to distinct statistical analysis.
Nakamura et al., determined association with chi-square
test, whereas in our study, correlation was computed with
spearman rank correlation. Another reason could be the
application of different antibody clones for activated MET
Y1234/1235 compared to the study of Nakamura et al.
phosphorylation at [Y1349] has not been investigated by
Nakamura et al. [36].
Unfortunately, association analysis between the ex-
pression and phosphorylation of MET with clinical
characteristics of the patients was not possible, because
we do not know anything about course of disease, e.g.
disease progression or treatment with TKIs.
Several studies have already been addressed to evaluate
the MET amplification status [7, 32, 37] by FISH. But,
previous studies used different criteria to define MET
amplification [7, 37, 38] in NSCLC. MET amplification
has been detected in up to ~5 % [36, 39, 40], whereas
an increased MET gene copy number was counted in
~20 % of patients with NSCLC by PCR based technique
[37, 41–43]. Inconsistence might be due to the genetic
alterations: gene amplification and polysomy. Bean et al.
determined MET gene amplification in 3 % of untreated
patients [37]. Cappuzzo et al. observed true gene amplifi-
cation in 4.1 % of 447 NSCLC patients [7]. In our study,
frequency of met gene amplification is 3.7 % matching
with the results of both referred reports given [7, 37].
Polysomy was detected in 2.3 % of the investigated tumor
samples. Correlation of MET gene amplification also in-
cluding polysomies showed no association with MET pro-
tein expression. These results are contrary to the study of
Dziadziuszko et al., who found significant correlation be-
tween MET gene copy number and MET protein expres-
sion [32]. One reason for that discrepancy could be due to
different IHC scoring systems, Dziadziuszko et al. did the
evaluation of IHC by using the H-score assessment. An-
other difference to our study is the use of SISH technology
by Dziadziuszko et al. compared to the FISH technique
we were conducting. Quantification of MET by IHC, west-
ern blot analysis and real time PCR was performed for a
subset of NSCLC tumor samples to figure out an idea of
whether there is any connection between these three
quantification methods. Strong correlation was observed
between IHC evaluation of MET protein expression and
western blot analysis. Apparently, no clear relationship ex-
ists between the expression on mRNA - and protein level.
Expression of MET on mRNA level seems to be less pro-
nounced than on protein level (Fig. 5). These differences
could be explained by posttranslational modifications or
degradation.
Unfortunately, we have almost no data about the
therapeutic management and the course of disease.
Finally, we have shown that there is a tendency of as-
sociation between MET and EGFR expression. Almost
tumor samples expressing MET are also positive for EGFR
expression. Cross-talk between MET and EGFR in NSCLC
has been previously shown by Acunzo et al. [44]. These
data are relevant to interpret the results of Benedettini
et al. [45]. In this study, MET protein expression and
phosphorylation have been associated with primary re-
sistance to EGFR-TKIs in patients with NSCLC. Also
Bean and colleagues observed MET amplification in 21 %
of patients with acquired resistance to EGFR-TKIs dem-
onstrating the crosstalk between both receptor signaling
pathways [37]. Thus, there could be a direct relationship
between co-expression of MET and EGFR and the respon-
siveness to EGFR-and or MET-targeting TKI. Data are
published showing that EGFR signaling is sufficient to
induce the phosphorylation of MET [46].
Conclusion
Our study depicts, that definition of MET positive signal-
ing together with MET-positivity might be required to
predict the benefit of MET targeting therapies. We
hypothesize that not MET expression is crucial for efficacy
of MET inhibitory molecules but the evaluation of the
activated RTK by determination of the phosphorylation
status of MET is more important. Phosphorylation and
thereby activation can also occur if MET is not over-
expressed; due to mutation or the activation of MET by
secreted HGF.
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In conclusion, investigation just of one receptor inde-
pendently of the quantification method might be ex-
tended to other RTKs, maybe the focus should not be
only on the expression level of RTKs, but on the deter-
mination of the activation status.
The results of this study might have consequential clinical
implication for therapeutic administration of MET specific
drugs, in particular for MET targeting TKIs, namely, that
not the expression alone might be of therapeutical relevance,
but also the determination of the phosphorylation status.
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